To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

Speeding Access to Already Approved Pharmaceuticals Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.